Eversept Partners, LP 13F Portfolio

CIK 1697013 Filing since Q4 2017 Q3 2026 filed Nov 16, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 16, 2026.

Portfolio Snapshot

105 positions · Q3 2026

Eversept Partners, LP reported 105 positions worth $1.73B for the quarter ended Sep 30, 2026, down 5.6% on the prior quarter. It opened 20 new positions, added to 31, trimmed 48 and exited 29. Its largest holding is UNITED THERAPEUTICS Corp at 10.2% of the portfolio.

Portfolio Value
$1.73B
-5.6% QoQ · +40.2% YoY
Positions
105
20 new · 29 sold out
Top 10 Concentration
50.9%
of portfolio value
Largest Position
UTHR 10.2%
UNITED THERAPEUTICS Corp
Net Buying
+$14.12M
$433.99M bought · $419.87M sold
Turnover
23.6%
of the portfolio traded
Top Sector
Healthcare
91.4% of value
Track Record
35
quarters on file since Q4 2017

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

5 sectors
91.37%
Healthcare
Healthcare91.37%
Real Estate7.57%
Technology0.954%
Other0.104%
Financial Services<0.01%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareReal EstateTechnologyOtherFinancial ServicesIndustrialsConsumer Staples

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
RVTY Revvity, Inc. +366.2K +437.9% $55.98M 3.97%
GH Guardant Health, Inc. +256.4K – $45.74M 2.64%
WAT Waters Corp +75.4K – $33.14M 1.91%
GRAL GRAIL, Inc. +182.2K – $25.52M 1.47%
OHI Omega Healthcare Investors Inc +525.0K +108.6% $24.31M 2.7%
ENSG Ensign Group, Inc +124.1K +20.6% $21.35M 7.21%
UTHR UNITED THERAPEUTICS Corp +37.1K +12.9% $20.08M 10.16%
ABVX Abivax S.A. +186.8K +20.4% $18.49M 6.29%
GDRX GoodRx Holdings, Inc. +5.02M – $16.51M 0.954%
ROIV Roivant Sciences Ltd. +419.1K – $15.33M 0.885%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
GSK GSK plc -481.8K -100.0% $25.26M Exited
IONS Ionis Pharmaceuticals Inc -543.0K -81.7% $24.24M 0.314%
LLY ELI LILLY & Co -20.1K -100.0% $24.13M Exited
TVTX Travere Therapeutics, Inc. -345.1K -43.2% $20.32M 1.54%
CLDX Celldex Therapeutics, Inc. -611.2K -34.2% $19.81M 2.2%
NTRA Natera, Inc. -47.7K -27.1% $19.71M 3.06%
AMN Amn Healthcare Services Inc -428.5K -100.0% $13.87M Exited
VRDN Viridian Therapeutics, Inc.DE -650.9K -78.3% $13.40M 0.214%
CELC Celcuity Inc. -127.9K -100.0% $13.38M Exited
HCA HCA Healthcare, Inc. -29.9K -30.5% $12.77M 1.68%

New Positions

Q3 2026
Holding Shares Trade Value Weight
GH Guardant Health, Inc. +256.4K $45.74M 2.64%
WAT Waters Corp +75.4K $33.14M 1.91%
GRAL GRAIL, Inc. +182.2K $25.52M 1.47%
GDRX GoodRx Holdings, Inc. +5.02M $16.51M 0.954%
ROIV Roivant Sciences Ltd. +419.1K $15.33M 0.885%
SUPN Supernus, Inc. +347.9K $14.97M 0.865%
ARWR Arrowhead Pharmaceuticals, Inc. +156.2K $10.22M 0.59%
SMMT Summit Therapeutics Inc. +526.6K $8.91M 0.514%
BNTX BioNTech SE +61.7K $6.06M 0.35%
ABCL AbCellera Biologics Inc. +254.1K $3.71M 0.214%

Closed Positions

Q3 2026
Holding Shares Sold Trade Value Prior Weight
GSK GSK plc -481.8K $25.26M 1.38%
LLY ELI LILLY & Co -20.1K $24.13M 1.32%
AMN Amn Healthcare Services Inc -428.5K $13.87M 0.756%
CELC Celcuity Inc. -127.9K $13.38M 0.73%
HUM Humana Inc -31.2K $12.38M 0.675%
ASND Ascendis Pharma A/S -41.6K $11.10M 0.605%
MRNA Moderna, Inc. -152.1K $10.65M 0.581%
DFTX Definium Therapeutics, Inc. -217.2K $10.22M 0.557%
CMPS COMPASS Pathways plc -672.8K $9.52M 0.519%
NVO Novo Nordisk A S -169.2K $8.11M 0.442%
Holdings · Q3 2026

105 Positions

As ofSep 30, 2026
Value$1.73B
Top 1050.9%
Avg position$16.49M
# Activity
90 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 105 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Eversept Partners.

About Eversept Partners, LP’s 13F Portfolio

What are Eversept Partners, LP’s largest holdings?

As of its Q3 2026 13F filing, Eversept Partners, LP’s five largest positions were UNITED THERAPEUTICS Corp (UTHR) at 10.2%, Encompass Health Corp (EHC) at 7.6%, Ensign Group, Inc (ENSG) at 7.2%, Abivax S.A. (ABVX) at 6.3%, Vera Therapeutics, Inc. (VERA) at 4.4% of the reported portfolio.

How much is Eversept Partners, LP’s portfolio worth?

Eversept Partners, LP reported a 13F portfolio worth $1.73B across 105 positions for Q3 2026. That is down 5.6% from the previous quarter.

What did Eversept Partners, LP buy in Q3 2026?

Its largest purchases by value were Revvity, Inc. ($55.98M), Guardant Health, Inc. ($45.74M), Waters Corp ($33.14M). It opened 20 new positions.

What did Eversept Partners, LP sell in Q3 2026?

Its largest sales by value were GSK plc ($25.26M), Ionis Pharmaceuticals Inc ($24.24M), ELI LILLY & Co ($24.13M). It exited 29 positions entirely.

Where does this data come from?

From the Form 13F-HR reports Eversept Partners, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.